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Subjects: Spironolactone and furosemide are commonly used for treatment of hepatic ascites, but the 
vasopressin V2 receptor inhibitor tolvaptan may also be added in cases that are treatment-resistant. 
The present study was conducted to clarify the factors affecting the therapeutic effectiveness of 
tolvaptan.
Methods: We studied 65 patients who were admitted to our hospital between September 2013 
and September 2018. Patients whose weight decreased by 1.5 kg or more one week after tolvaptan 
administration were defined as responders（R）, and compared with non-responders（NR）.
Results: The two groups were compared in terms of age, cause of liver cirrhosis, presence of 
esophageal varices, presence of hepatocellular carcinoma, dose of furosemide, dose of spironolactone, 
albumin, T-bilirubin, PT%, and creatinine. Serum Na levels were significantly higher in R patients 
with significantly lower BUN. R patients survived significantly longer than NR patients. There 
was significant difference in survival rate between patients with a Na level of 138 mEq/L or less 
than for those with a Na level of 139 mEq/L or more.　The main factor related to good treatment 
responsiveness in patients receiving tolvaptan was absence of any decrease in serum Na and a stable 
BUN level. 
Conclusion: The factors related to the effectiveness of tolvaptan for treatment of ascites are a 
decrease in Na and an increase in BUN.
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Introduction
Decompensated cirrhosis has a poor prognosis 
once hepatic ascites has developed１）.
Such patients are usually treated orally with the 
diuretics furosemide and spironolactone, together 
with administration of albumin, ascites puncture 
drainage, and cell-free concentrated ascites reinfusion 
therapy（CART）２），３）.
In poor responders, the prognosis is generally poor, 
and many suffer concomitant renal failure and death. 
The vasopressin V2 receptor inhibitor tolvaptan is 
known to be more effective for improving ascites 
in view of its strong diuretic effect４）, and in recent 
years it has been used in combination for cases 
resistant to spironolactone and furosemide５）.
Tolvaptan exerts its diuretic effect by suppressing 
both the expression of aquaporin-2（a water 
channel）and the reabsorption of water through 
vasopressin V2-receptor antagonism in the collecting 
duct of the kidney. Thus, it exerts a stronger effect 
than other diuretics５）－８）. However, the diuretic 
effect of tolvaptan is known to vary from case to 
case, and some patients thus treated still show a 
poor prognosis９）. Kogiso et al. have also reported 
ABSTRACT
Yamagata Med J （ISSN 0288-030X）2020；38（2）：69-74
DOI 10.15022/00004880
－70－
Okumoto， Saito， Nishina， Mizuno， Katsumi， Hoshikawa， Haga， Ueno
that the response to tolvaptan is dependent of the 
serum levels of BUN and Na10）. However, the factors 
associated with long-term prognosis in patients with 
cirrhosis receiving tolvaptan have remained unclear. 
Here we investigated these factors and examined the 
prognosis of patients thus treated.
Material and Methods
This was retrospective observation study 
undertaken in single hospital. The subjects were 
65 patients with hepatic ascites（40 males and 
25 females, aged 69.4±7.9 years）who were 
admitted to our department between September 
2013 and September 2018. All were administered 
tolvaptan at 7.5mg/day for 1 week or more. Prior 
to administration, furosemide at 45.2±31.5mg/
day and spironolactone at 36.7±20.4mg/day had 
been administered. Patients whose body weight 
decreased by 1.5kg or more one week after the start 
of administration were defined as responders（R）, 
and the rest were defined as non-responders（NR）11）. 
These two groups were compared for related factors 
and prognosis. They were also divided and compared 
on the basis of creatinine and serum sodium values. 
Student’s t test and χ2 test were used for statistical 
analysis, and the R and NR groups were subjected to 
multivariate analysis.
Results
There were 37 R patients and 28 NR patients. 
The two groups were compared in terms of age, sex 
ratio, cause of liver cirrhosis, presence or absence 
of esophageal varices, presence or absence of liver 
cancer, dose of furosemide, dose of spironolactone, 
albumin, T-bilirubin, prothrombin time %, and 
creatinine（Table１）. In R patients BUN was 
0
 
Table1. Characteristics of patients with cirrhosis and ascites, grouped according to 
treatment response to tolvaptan 
Characteristics 
 
Total 
(n=65) 
Responders
(n=37) 
Non-responders 
(n=28) 
P-value 
Age, years 
 
69.4±7.9 68.7±8.2 70.2±7.5 NS 
Sex(male/female) 
 
40/25 23/14 17/11 NS 
HCV/Alcohol/NASH/ 
PBC/Others 
 
38/12/5/4/6 21/8/4/2/2 17/4/1/2/4 NS 
HCC(Yes/No) 29/36 15/22 14/14 NS 
Child-Pugh 
score(A/B/C) 
6/56/3 2/25/1 4/31/2 NS 
Varices(Yes/No) 42/23 24/13 18/10 NS 
Body weight kg 59.3±13.3 61.9±15.2 55.9±9.4 NS 
Dose of furosemide 
before treatment 
mg 45.2±31.5 43.9±30.9 46.8±32.7 NS 
Dose of 
Spironolactone 
before treatment 
mg 36.7±20.4 37.8±22.5 35.2±17.3 NS 
Alb g/dl 2.68±0.50 2.69±0.54 2.66±0.45 NS 
T-bil mg/dL 1.97±2.07 1.61±1.26 2.43±2.76 NS 
PT% % 72.4±21.8 72.8±24.6 71.9±17.9 NS 
BUN mg/dL 24.5±15.4 20.5±10.5 29.7±19.1 P<0.05 
Cre mg/dL 1.00±0.61 0.90±0.42 1.14±0.79 NS 
Serum Na mEq/L 137.6±4.0 138.8±3.6 136.1±4.0 P<0.01 
NASH : Nonalcoholic steatohepatitis 
PBC : Primary biliary cholangitis 
HCC : Hepatocellular carcinoma  
 
 
Table１．Characteristics of patients with cirrhosis and ascites, grouped according to treatment response to tolvaptan
　The two groups were compared in terms of age, sex ratio, cause of liver cirrhosis, presence or absence of 
esophageal varices, presence or absence of liver cancer, dose of furosemide, dose of spironolactone, albumin, T-bilirubin, 
prothrombin time %, and creatinine.
－71－
The factors related to the effectiveness of tolvaptan
significantly lower（20.5±10.5 vs. 29.7±19.1mg/dL 
dl, p <0.05）whereas the Na level was significantly 
higher（138.8±3.7 vs. 136.1±4.0 mEq/L, p<0.01）. 
Only the serum Na level was shown to be significant 
by multivariate analysis（Table２）. There were no 
significant differences between BUN and creatinine at 
7 days after tolvaptan administration, but serum Na 
levels were significantly elevated in both the R and 
NR groups（Figure１）. Albumin showed a tendency 
to increase in R patients one week after tolvaptan 
administration, T-bilirubin decreased significantly, 
and prothrombin time increased significantly（Figure 
２）. Survival was significantly longer in R patients 
than in NR patients（50.3 vs 9.0 months, p＜0.01: 
log rank test）（Figure３）. There was no significant 
difference in survival rate between patients with a 
creatinine level of 0.9mg/dL or less and those with 
a creatinine level of 1.0mg/dL or more, but survival 
rate was significantly better in patients with a serum 
Na level of 139 mEq/L than in those with a serum 
Na level of 138 mEq/L or less（Figures４，５）.
1 
 
Table2. Logistic analysis for response to treatment with tolvaptan at 7.5 mg/day for 7 
days in liver cirrhosis patients with ascites 
 
 
Factor 95%CI Hazard ratio P-Value 
Dose of furosemide before treatment 0.9796-1.0281 1.0035 0.7747 
Dose of Spironolactone before treatment 0.9877-1.0596 0.9877 0.2034 
Alb before treatment 0.2531-3.1373 0.2531 0.8575 
T-bil before treatment 0.4632-1.2056 0.4632 0.2326 
PT% before treatment 0.9643-1.0299 0.9643 0.8371 
BUN before treatment 0.8777-1.0359 0.8777 0.2601 
Cre before treatment 0.2008-9.1108 0.2008 0.7564 
Serum Na before treatment 1.0114-1.4539 1.2126 0.0373* 
Body Weight before treatment 0.9696-1.0765 1.0217 0.4213 
 
Table２．Logistic analysis for response to treatment with tolvaptan at 7.5 mg/day 
for 7 days in liver cirrhosis patients with ascites
　Only the serum Na level was shown to be significant by multivariate analysis.
Figure1.
(mg/dL)
(a)BUN  (b)Cre (c)Serum Na
(mg/dL)
(mEq/L)
P<0.05
P<0.05
NS
NS
NS NS
126
128
130
132
134
136
138
140
142
144
146
0
5
10
15
20
25
30
35
40
45
50
BUN bfore
treatment
BUN after
7days
0.0
0.5
1.0
1.5
2.0
2.5
Responder
Non-responder
Cre after 
7days
Cre before 
treatment
Serum Na  
after 7days
Serum Na 
before treatment
Figure2.
(a)Alb (b)T-bilirubin (c)PT%
Responder
Non-responder
2.0
2.2
2.4
2.6
2.8
3.0
3.2
3.4
Alb before
treatment
Alb after
7days
0.0
1.0
2.0
3.0
4.0
5.0
6.0
40
50
60
70
80
90
100
PT% before
treatment
PT% after
7days
(mg/dL) (％)
(g/dL) P<0.01
P<0.05
NS
NS
NS
NS
T-bil after 
7days
T-bil before 
treatment
Figure１. There were no signif icant differences 
between BUN and creatinine at 7 days after tolvaptan 
administration, but serum Na levels were significantly 
elevated in both the R and NR groups.
Figure２. Albumin showed a tendency to increase in 
R patients one week after tolvaptan administration, 
T-bilirubin decreased significantly, and prothrombin time 
increased significantly.
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Discussion
Tolvaptan selectively inhibits the vasopressin V2 
receptor in renal collecting ducts12）. Patients with 
hepatic ascites are administered spironolactone 
as a first-line drug, followed by administration of 
furosemide13），14）. Tolvaptan is used in combination 
with these exist ing diuret ics i f  there is no 
improvement in the ascites15）. In our present series, 
the NR group had significantly lower serum Na 
levels. As production of ascites worsens, activities 
of daily living（ADL）and nutritional conditions 
deteriorate, and the prognosis becomes poor. Various 
reports have documented the effectiveness of 
tolvaptan in patients with ascites16），17）. In this study, 
serum Na was significantly higher in the R group, 
whereas BUN was significantly lower, and the effect 
of initially administered diuretics appeared to be less 
marked.
S imi lar observat ions have been reported 
elsewhere, and our findings are consistent with a 
previous reports.18）－21）. The reduction in serum Na 
is attributable of the effects of preceding diuretics, 
especially furosemide, whereas the high BUN level 
thought to be due to dehydration of blood vessels 
and a decrease in renal blood flow. These conditions 
are evident in NR patients and account for their poor 
prognosis. R patients showed an elevated albumin 
level and a decreased bilirubin level, indicating 
a significant improvement of liver reserve and 
nutritional status through increased food intake and 
decreased production of ascites. There was also a 
Figure3.
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Figure３. Survival was significantly longer in R patients 
than in NR patients （50.3 vs 9.0 months, p＜0.01: log rank 
test）．
Figure４. There was no significant difference in survival 
rate between patients with a pretreatment creatinine 
level  of 0.9 mg/dL or less and those with a creatinine 
level of 1.0 mg/dL or more.
Figure５. Survival rate was significantly better in patients 
with a pretreatment serum Na level of 139 mEq/L than 
in those with a serum Na level of 138 mEq/L or less. （p＜ 
0.01: log rank test）．
Figure5.
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significant increase in the serum Na level, consistent 
with a previous report18）. Furthermore, the survival 
rate was significantly better in R patients and in 
patients without a reduction in the Na level. Similar 
reports have indicated that R patients have a better 
prognosis22），23）. However, few previous studies have 
examined the long-term prognosis of such patients, 
and the present study appears to be the first to have 
done so. Although the dose of tolvaptan administered 
to such patients has been controversial, all of the 
present patients received 7.5mg. In some cases, a 
urine volume of 1000ml/day or more was achieved, 
and there were also cases in which a small amount 
was considered to be acceptable. In one study, a dose 
of 3.75mg was reported to be effective, but further 
investigation of this issue will be necessary24）. The 
main factor related to good treatment responsiveness 
in patients receiving tolvaptan was absence of any 
decrease in serum Na and a stable BUN level. 
Conclusion
Our present report is the first to indicate that 
tolvaptan has a favorable impact on the prognosis 
of patients with liver cirrhosis. In particular, for 
patients with a decreased serum Na level that 
can adversely affect prognosis, it is important to 
administer tolvaptan before such a decrease becomes 
apparent.
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